Uveal Melanoma Treatment Market Report Scope & Overview:

The Uveal Melanoma Treatment Market was valued at USD 1.59 Billion in 2025 and is expected to reach USD 2.95 Billion by 2035, growing at a CAGR of 6.39% from 2026-2035.

The Uveal Melanoma Treatment Market growth is being driven mainly by the novel survival advantage provided by tebentafusp. In addition to that, there are expanding incentives for the use of orphan drugs as well as quick developments in the field of gene therapies and cell therapies. AI-enabled screenings are increasing the chances of identifying the primary tumors at an early stage. Breakthrough designations for darovasertib and other kinase inhibitors continue to shorten development timelines, and novel ocular delivery platforms are reducing systemic toxicity while enhancing product differentiation. Disease-specific systemic treatment has meaningfully changed care for HLA-A*02:01-positive metastatic disease, while liver-directed treatment creates an additional commercial pathway given that the liver remains the dominant metastatic site for this rare, aggressive form of eye cancer.

IDEAYA Biosciences and Servier reported positive Phase 2/3 OptimUM-02 results for darovasertib plus crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma, with U.S. filing underway. The findings expand targeted treatment development beyond tebentafusp’s eligible population, supporting broader disease-specific therapeutic options for patients with metastatic uveal melanoma worldwide.

Uveal Melanoma Treatment Market Trends

• Disease-specific systemic treatment for HLA-A*02:01-negative metastatic disease is expanding through darovasertib plus crizotinib registrational programs.

• Liver-directed treatment pathways are gaining commercial traction as the liver remains the dominant metastatic site for uveal melanoma.

• AI-supported screening tools are raising detection rates of primary tumors at a treatable stage, expanding the eligible patient pool for eye-preserving procedures.

• Novel ocular drug-delivery platforms, including suprachoroidal delivery and sustained-release implants, are reducing systemic toxicity for advanced-stage patients.

• Companion diagnostics and liquid-biopsy assays are opening new revenue streams through risk stratification and post-treatment surveillance.

• Adjuvant treatment trials for high-risk primary disease are advancing, with successful recurrence-prevention approaches poised to create demand before metastatic progression.

U.S. Uveal Melanoma Treatment Market Outlook

The U.S. Uveal Melanoma Treatment Market was valued at USD 390.02 Million in 2025 and is expected to reach USD 645.63 Million by 2035, growing at a CAGR of 5.17% from 2026-2035.

The U.S. Uveal Melanoma Treatment Market is being bolstered by FDA guidance regarding orphan drug policy, a rich ocular oncology community, and venture investments, which take place primarily out of Boston and California’s biotechnology cluster. In 2022, tebentafusp received FDA approval for HLA-A*02:01-positive adults with unresectable and metastatic disease, and HEPZATO KIT has recently been approved in 2023 for the treatment of certain adults with unresectable hepatic metastases. Reimbursements for high-cost diagnostic markers have become more widespread domestically; however, prior authorizations continue to be challenging for smaller specialist institutions.

The FDA endorsed IDEAYA Biosciences' Phase 3 darovasertib neoadjuvant trial design, enrolling 520 patients with primary uveal melanoma. The trial focuses on eye preservation and vision outcomes, following breakthrough therapy designation after Phase 2 demonstrated 82% ocular tumor shrinkage and 61% eye preservation, supporting accelerated development for rare ocular oncology indications.

Uveal Melanoma Treatment Market Segment Analysis

• By Therapy Type, the Radiation Therapy segment dominated the Uveal Melanoma Treatment Market with approximately 34.80% share in 2025, while the Gene Therapy segment is the fastest growing with a CAGR of approximately 7.48%.

• By Drug Class, the Immune Checkpoint Inhibitors segment dominated the Uveal Melanoma Treatment Market with approximately 35.12% share in 2025, while the Protein Kinase Inhibitors segment is the fastest growing with a CAGR of approximately 6.44%.

• By Disease Stage, the Primary Uveal Melanoma segment dominated the Uveal Melanoma Treatment Market with approximately 54.22% share in 2025, while the Metastatic Uveal Melanoma (Liver) segment is the fastest growing with a CAGR of approximately 5.80%.

• By Route of Administration, the Intravenous segment dominated the Uveal Melanoma Treatment Market with approximately 46.90% share in 2025, while the Localized Implant Delivery segment is the fastest growing with a CAGR of approximately 7.65%.

• By End Use, the Hospitals segment dominated the Uveal Melanoma Treatment Market with approximately 39.83% share in 2025, while the Academic & Research Institutes segment is the fastest growing with a CAGR of approximately 6.05%.

• By Patient Age Group, the Adult Patients segment dominated the Uveal Melanoma Treatment Market with approximately 69.30% share in 2025, while the Geriatric Patients segment is the fastest growing with a CAGR of approximately 7.15%.

By Therapy Type, Radiation Therapy Dominates and Gene Therapy Grows Fastest

Radiation therapy dominates the Uveal Melanoma Treatment Market in 2025, Being reflective of the immediate aim of treating the main disease in the form of local control, plaque brachytherapy and proton beam radiotherapy help the doctors treat ocular tumors without having to sacrifice the eye. In this way, radiotherapy has become an integral part of the treatment procedure. Both therapies provide a form of treatment that specifically treats the tumors and minimizes the exposure of adjacent tissues. The usefulness of these therapies is also backed up by the fact that they have been clinically used in the past and continue to be used in current guidelines for localized ocular cancers.

Gene therapy is expanding fastest as viral-vector refinement and local delivery approaches achieve higher ocular drug concentrations with lower systemic load, positioning the modality as a growing competitive alternative to legacy immune regimens. Precision delivery platforms designed to cross the blood-retina barrier without extensive invasive procedures are demonstrating potential for durable tumor control and vision preservation in early clinical trials. Continuous advancements in vector technology and targeted delivery have been stimulating increasing interest in genetic approaches to treating uveal melanoma. The research area is expanding, with nanocarriers and non-viral vectors becoming increasingly popular, creating new possibilities for increasing therapy precision and prolongation, as well as improving ocular drug delivery.

By Drug Class, Immune Checkpoint Inhibitors Dominates and Protein Kinase Inhibitors Grows Fastest

Immune checkpoint inhibitors dominate the Uveal Melanoma Treatment Market in 2025, though response rates are lower compared to cutaneous melanomas, there are many precedents of high physician awareness, clinical experience, and reimbursement that support their usage. They still play an important role in treating advanced cases, especially in situations where alternative therapy cannot be used. There are many combination therapies that utilize checkpoint blockade in combination with some other therapy in order to combat the natural immune resistance that is specific for uveal melanoma’s unique pathobiology. Clinical trials are also working on optimizing combination and sequence of treatment as well as increasing the immune activation through various methods.

Protein kinase inhibitors are growing fastest on the strength of darovasertib's breakthrough therapy status and promising ocular preservation outcomes demonstrated in Phase 2 trials. New research on intracellular targets is expanding the arsenal of therapeutics, with the newer modalities becoming increasingly focused on interfering with the molecular mechanisms responsible for promoting the growth and survival of uveal melanoma cells. Dual targeting and novel small molecules are under investigation to circumvent resistance and enhance control over the disease. As research progresses, these targeted treatments may become available for patients with limited options. Future evaluation of efficacy, safety, vision preservation, and longevity of the effect will help position the most promising drug classes as the registrational data evolves.

By Disease Stage, Primary Uveal Melanoma Dominates and Metastatic Uveal Melanoma (Liver) Grows Fastest

Primary uveal melanoma dominates the Uveal Melanoma Treatment Market in 2025, The rationale for this approach is based on the prior diagnosis and the advancement in surgical approaches that spare the eye. Management involves dealing with the primary ocular tumor via brachytherapy, proton therapy, local resection or enucleation depending on the size and location of the tumor and the possibility of vision conservation. The possibilities allow for management that is tailored according to the specific features of the disease. As such, the primary disease represents the gateway to the overall treatment process.

Metastatic uveal melanoma affecting the liver is expanding fastest, anchored by tebentafusp's demonstrated survival edge and percutaneous hepatic perfusion techniques that nearly triple progression-free intervals for affected patients. Neoadjuvant kinase inhibition trials showing substantial tumor shrinkage alongside meaningful eye preservation rates suggest a future shift toward systemic therapy before local resection. At the same time, liquid biopsy assays detecting circulating tumor DNA are increasingly informing adjuvant treatment decisions. These developments are broadening treatment strategies for metastatic disease while supporting more personalized approaches to disease monitoring and therapeutic planning.

By Route of Administration, Intravenous Dominates and Localized Implant Delivery Grows Fastest

Intravenous administration dominates the Uveal Melanoma Treatment Market in 2025, the text is an indication of the oncology specialty practice where the treatment of advanced uveal melanoma occurs. Tebentafusp is given through an intravenous infusion on a weekly basis, and early doses are given under monitoring since they cause acute side effects of the treatment. The availability of infusions is therefore important in the management of metastatic cases through systemic therapy. This method of administration also facilitates the management of the patient under special oncology care.

Localized implant delivery is expanding fastest as sustained posterior-segment delivery platforms gain commercial acceptance following validation from implantable reservoir technologies already approved for other ocular indications. Biodegradable devices and polymer nanoparticles are further reducing surgical burden while permitting controlled release of kinase inhibitors or immune modulators, improving tolerability profiles that differentiate next-generation therapeutic entrants. These approaches can support prolonged drug exposure within targeted ocular tissues while potentially reducing the frequency of administration. Continued advances in ocular drug-delivery technologies are therefore strengthening interest in localized treatment strategies for uveal melanoma.

By End Use, Hospitals Dominates and Academic & Research Institutes Grows Fastest

Hospitals dominate the Uveal Melanoma Treatment Market in 2025, It is becoming more and more common for hospitals to bring together surgery, radiation, and systemic oncology in one place, for the management of uveal melanoma. This disease requires both eye surgery and systemic cancer treatments, and this makes it difficult to distribute its management among various institutions. Plaque application, radiation, enucleation, liver-based treatments, and infusion monitoring all require specialists, sophisticated imaging, and operating rooms or radiation suites. Hospitals also provide an integrative setting for bringing together ophthalmologists, oncologists, radiologists, and surgery teams.

Academic and research institutes are growing fastest, given the importance of the centers in the early phases of clinical trials, translational research, and new methods of treatment, they continue to be key players in medical advancement. Given the over 40 active protocols that they have in various clinical studies, they act as gatekeepers of innovative treatments and experimental treatments. Through their research capacity, they are able to test novel systemic and ocular Treatments as part of the process of gathering information for future clinical use. Tele-oncology and satellite clinics ensure that expertise is taken to areas that lack it through making trials accessible to eligible candidates.

By Patient Age Group, Adult Patients Dominates and Geriatric Patients Grows Fastest

Adult patients dominate the Uveal Melanoma Treatment Market in 2025, as uveal melanoma is primarily an adult malignancy with incidence generally rising with age. Pediatric uveal melanoma remains uncommon, resulting in a relatively limited pediatric patient population compared with adults. Consequently, adult-focused clinical evidence continues to shape most local and systemic treatment protocols across specialist ocular oncology centers. Treatment approaches are increasingly guided by established clinical experience, disease characteristics, and patient-specific considerations, while ongoing research continues to evaluate improved therapeutic strategies for managing uveal melanoma among adult patients across specialized healthcare settings.

Geriatric patients are growing fastest as improved surveillance programs and genetic counseling widen the addressable patient pool among older populations, who carry the highest baseline incidence of uveal melanoma. Expanded screening initiatives, combined with AI-driven fundus analysis, are supporting earlier identification and intervention in this age group. These developments are improving the ability of ophthalmic specialists to detect suspicious lesions during routine examinations and facilitate timely clinical assessment. As a result, the case mix is gradually shifting toward treatable primary disease detected through routine ophthalmic examination, supporting increasing treatment demand among geriatric patients.

Regional Analysis

North America Uveal Melanoma Treatment Market Insights

North America accounted for approximately 29.05% of the global Uveal Melanoma Treatment Market in 2025, the largest share of any region, benefiting from FDA leadership on orphan-drug incentives and a dense network of ocular oncology specialists. The United States drives the substantial majority of regional demand, supported by the FDA's approval of tebentafusp in 2022 and HEPZATO KIT in 2023, which together created distinct systemic and liver-directed treatment pathways for eligible patients.

Canada and Mexico contribute a smaller but steadily growing share of regional revenue as reimbursement pathways for high-value biomarker tests gain traction and specialist ocular oncology capacity gradually expands across the region. Regional venture capital concentrated around leading North American biotechnology hubs continues to fund early-stage rare-oncology development relevant to uveal melanoma.

Europe Uveal Melanoma Treatment Market Insights

Europe represents a strong regional market due to widespread coverage by the health schemes of the nations and strong collaboration in research across borders through EURACAN network. The region enjoys extensive radiation experience and established surgical procedures while growing preference for gene expression profiling keeps gaining ground. Although health technology assessment delays the market entry process, it helps in establishing steady revenue streams through reimbursement of the costs incurred.

Germany is the front-runner in terms of regional adoption due to effective health technology assessment system. This can be demonstrated by reassessment of tebentafusp by G-BA in 2024 for HLA-A*02:01 positive unresectable or metastatic cancer following the drug crossing the orphan drug turnover threshold. There is growth in accessibility in the UK as well following recommendation of the drug by NICE in January 2025 for tebentafusp in a commercial arrangement.

Asia Pacific Uveal Melanoma Treatment Market Insights

Asia Pacific is the fastest-growing regional market that is forecast to witness growth at an estimated CAGR of around 7.21% during the period 2026-2035 owing to fast development of ophthalmology infrastructure, increase in insurance penetration, and advancements in regulations, although incidence rates continue to be low. Among countries, China holds the position of being the largest market on account of NMPA approvals for novel immunotherapies and a rising pool of oncology specialists.

Japan, despite low occurrence rates of uveal melanoma, offers significant know-how in immunotherapy and treatment is mostly performed in specialized centers and centers actively participate in global clinical trials. In South Korea and Australia, there are ongoing investments in diagnostic technologies based on AI and development of ophthalmology infrastructure.

MEA & Latin America Uveal Melanoma Treatment Market Insights

The Middle East & Africa region is led by the GCC countries, where growing healthcare investment and expanding specialist ophthalmology infrastructure are gradually increasing access to disease-specific systemic treatment and liver-directed therapy options. South Africa represents the largest contributor within the African portion of the region, supported by a comparatively developed private oncology network, while broader regional adoption remains constrained by limited access to ocular radiation and advanced clinical trials.

The Latin American market is dominated by Brazil, whose market share after the approval of tebentafusp by ANVISA in February 2025 for adults HLA-A*02:01-positive with unresectable or metastatic condition is highest among the other regions. Tebentafusp approval has provided the national regulatory process for the treatment of such diseases. Market adoption is limited to specialty cancer hospitals since the proper use of the treatment depends on the ability of oncology infrastructure that tests the patients, administers intravenous administration and management of early side effects.

Market Dynamics

Growth Drivers: HLA-Directed Therapy and Rising Uveal Melanoma Incidence

Growth in the Uveal Melanoma Treatment Market is fundamentally supported by the first-in-class survival benefit demonstrated by tebentafusp for HLA-A*02:01-positive metastatic disease, alongside rising global incidence of uveal melanoma driven by improved surveillance programs and genetic counseling. Incidence rates stand notably higher in North America and Europe compared with major Asian populations, and expanded screening combined with AI-driven fundus analysis is shifting case mix toward earlier, more treatable primary disease across all major markets.

Favorable orphan-drug and fast-track regulatory approvals, led primarily by the U.S. FDA, continue to shorten development timelines for gene-based, cell-based, and targeted therapies addressing this rare malignancy. Growing private funding for rare oncology, concentrated around North American and European venture ecosystems, is balancing the high cost of individualized care with promising long-term commercial returns for developers advancing next-generation treatment modalities.

Restraints: High Treatment Costs and Limited Patient Pool

The expensive cost of personalization therapy is one of the growth restraining factors in the segment, where tebentafusp is priced over USD 400,000 per annum and biomarker-based tests add to the upfront costs. Gaps in the access to treatment arise when there are few centers of ocular oncology specialists, favoring tele-oncology approaches and creating reimbursement issues that can hinder utilization of the product regardless of the evident survival benefits it offers.

The number of new patients diagnosed with uveal melanoma globally is only a few thousand annually. Therefore, conducting of large Phase III clinical studies is not feasible in terms of both recruitment and timing for sponsors. The requirement to be HLA-A*02:01 positive reduces the potential patient pool to about half of all Caucasians. The willingness of regulators to allow adaptive trials and surrogate endpoints partially resolves this challenge.

Opportunities: HLA-Negative Targeted Therapy and Adjuvant Treatment Expansion

The extension of late-stage targeted therapy development beyond the HLA-A*02:01-positive population represents a significant opportunity, as darovasertib-based combination regimens broaden disease-specific treatment access to patients previously left without a targeted therapeutic option. Continued refinement of ocular drug-delivery platforms, including suprachoroidal delivery and non-viral nano-carriers, offers manufacturers a pathway to safer repeat dosing and improved tolerability that could reshape competitive positioning across the therapeutic landscape.

Adjuvant treatment trials targeting high-risk primary disease, alongside companion diagnostic and liquid-biopsy innovation for risk stratification, are opening substantial white-space opportunities ahead of metastatic progression. New market access following national regulatory approvals across Brazil and other emerging markets offers developers a durable runway for geographic expansion beyond the mature North American and European markets that currently anchor global revenue.

Recent Developments:

• 2026, Aura Biosciences completed enrollment in its Phase 3 CoMpass trial of bel-sar for early choroidal melanoma, with topline data expected in 2027, advancing a virus-like drug conjugate approach toward primary-disease treatment.

• 2025, ANVISA registered tebentafusp for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, creating a new national regulatory route for disease-specific systemic treatment in Brazil.

• 2025, NICE recommended tebentafusp for eligible adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma under a commercial arrangement, creating a funded NHS pathway for advanced disease in the United Kingdom.

• 2025, Genentech gained FDA approval for Susvimo continuous delivery technology in diabetic macular edema, validating sustained ocular implant technology that is applicable to future uveal melanoma drug-delivery platforms.

• 2025, Castle Biosciences presented DecisionDx-Melanoma data linking the assay to a 32% mortality risk reduction across 13,500 patients and introduced a 16-protein liquid-biopsy test for small uveal tumors, strengthening companion diagnostic capabilities for risk stratification.

Uveal Melanoma Treatment Market Key Players

• Immunocore Holdings plc

• Delcath Systems, Inc.

• IDEAYA Biosciences, Inc.

• Servier

• Aura Biosciences, Inc.

• Merck & Co., Inc.

• Bristol Myers Squibb

• Eli Lilly and Company

• Novartis AG

• Bayer AG

• AstraZeneca plc

• F. Hoffmann-La Roche AG

• Daiichi Sankyo Co., Ltd.

• iOnctura SA

• Regeneron Pharmaceuticals, Inc.

• Pfizer Inc.

• Castle Biosciences, Inc.

• Genentech, Inc.

• Incyte Corporation

• Genmab A/S

Uveal Melanoma Treatment Market Report Scope: